Thanks to the success of its COVID-19 vaccine, the drug giant Pfizer has become a household name around the globe—and the company’s eyeing $ 15 billion in sales from the shot this year. For writing that 2020 success story, CEO Albert Bourla collected a pay package worth more than $ 21 million. Bourla, who took… Read More »
After years of manufacturing woes, Pfizer appeared to turn a corner earlier this year for its growing sterile injectables portfolio. But even with signs trending upward, Pfizer is preparing to exit an Australian site specializing in those drugs as part of a global reorganization effort. Pfizer will walk away from its more than 50-year-old facility in… Read More »
Several pharma giants—including Merck, Novartis, Eli Lilly and Pfizer—have just lost procurement deals in China under the country’s new bidding system. The drugmakers lost out to domestic producers, which in some cases undercut prices for established medicines by more than 90%, according to Jiemian. Among the drugs to lose contracts were Eli Lilly schizophrenia medicine Zyprexa and Pfizer’s Viagra, the publication said. This week’s… Read More »
Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching biosims to three Roche cancer blockbusters at discounts ranging from 22% to 24%. The company has already rolled out Zirabev and Ruxience, its biosimilars to Roche’s Avastin and Rituxan, respectively, at discounts of 23% and 24%. On… Read More »